Dermata Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
DRMA$0.76+0.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets: | ||
| Cash and cash equivalents | $6,945,282 | $7,521,978 |
| Prepaid expenses and other current assets | 427,279 | 341,848 |
| Inventory | 93,091 | - |
| Total assets | $7,465,652 | $7,863,826 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable (including related party amounts of $0 and $86,250, respectively) | $318,331 | $460,811 |
| Accrued and other current liabilities (including related party amounts of $129,333 and $25,000, respectively) | 734,318 | 1,179,635 |
| Total liabilities | 1,052,649 | 1,640,446 |
| Commitments and Contingencies (see Note 6) | ||
| Stockholders’ Equity: | ||
| Common Stock, par value $0.0001, 250,000,000 shares authorized; 4,022,143 shares issued and outstanding as of March 31, 2026; 2,660,110 shares issued and outstanding as of December 31, 2025. | 402 | 266 |
| Additional paid-in capital | 81,494,203 | 79,457,010 |
| Accumulated deficit | (75,081,602) | (73,233,896) |
| Total stockholders’ equity | 6,413,003 | 6,223,380 |
| Total liabilities and stockholders’ equity | $7,465,652 | $7,863,826 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.